Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction

Michael D. Miedema, Jay N Cohn, Ross F. Garberich, Thomas Knickelbine, Kevin J. Graham, Timothy D Henry

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Multiple medications have proven efficacy for the primary prevention of coronary heart disease (CHD), but the appropriate patient population remains controversial. Even in the presence of multiple cardiovascular risk factors, many patients are not considered high risk and are not offered preventive medications despite proven efficacy. Methods: We analyzed a prospective cohort of 1,710 consecutive ST-elevation myocardial infarction (STEMI) patients treated in a regional STEMI system from May 2007 to July 2010 and enrolled in a comprehensive database that includes preadmission medications. Results: Of the 1,707 patients analyzed, 1,180 (69.1%) did not have known CHD before their event; and 482 (41.7%) of those patients had premature events (men < 55 years old, women < 65 years old). In patients without known CHD, cardiovascular risk factors were abundant (52.1% had hypertension, 43.6% had dyslipidemia, 41.4% had a family history of CHD, 58.5% were current or former smokers, and 14.9% were diabetic). Despite the high prevalence of risk factors, only 24.1% were on aspirin, 16.1% were on a statin, and only 7.8% were taking an aspirin and statin. Use of preventive medications was even less common in patients with premature events, including aspirin (15.2% vs 30.2%, P value <.001), statins (11.1% vs 19.5%, P value <.001), and the combination (5.6% vs 9.4%, P value <.001). Conclusions: Approximately 70% of a contemporary STEMI population did not have known CHD before their event, and > 40% of those events would be considered premature. Despite the significant burden of cardiovascular risk factors, use of preventive therapy was alarmingly low in patients presenting with STEMI.

Original languageEnglish (US)
Pages (from-to)259-267
Number of pages9
JournalAmerican Heart Journal
Volume164
Issue number2
DOIs
StatePublished - Aug 1 2012

Fingerprint

Drug Therapy
Coronary Disease
Primary Prevention
ST Elevation Myocardial Infarction
Databases
Population
Therapeutics

Cite this

Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction. / Miedema, Michael D.; Cohn, Jay N; Garberich, Ross F.; Knickelbine, Thomas; Graham, Kevin J.; Henry, Timothy D.

In: American Heart Journal, Vol. 164, No. 2, 01.08.2012, p. 259-267.

Research output: Contribution to journalArticle

Miedema, Michael D. ; Cohn, Jay N ; Garberich, Ross F. ; Knickelbine, Thomas ; Graham, Kevin J. ; Henry, Timothy D. / Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction. In: American Heart Journal. 2012 ; Vol. 164, No. 2. pp. 259-267.
@article{39f2efbde76c46c89a6964975fbdee45,
title = "Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction",
abstract = "Background: Multiple medications have proven efficacy for the primary prevention of coronary heart disease (CHD), but the appropriate patient population remains controversial. Even in the presence of multiple cardiovascular risk factors, many patients are not considered high risk and are not offered preventive medications despite proven efficacy. Methods: We analyzed a prospective cohort of 1,710 consecutive ST-elevation myocardial infarction (STEMI) patients treated in a regional STEMI system from May 2007 to July 2010 and enrolled in a comprehensive database that includes preadmission medications. Results: Of the 1,707 patients analyzed, 1,180 (69.1{\%}) did not have known CHD before their event; and 482 (41.7{\%}) of those patients had premature events (men < 55 years old, women < 65 years old). In patients without known CHD, cardiovascular risk factors were abundant (52.1{\%} had hypertension, 43.6{\%} had dyslipidemia, 41.4{\%} had a family history of CHD, 58.5{\%} were current or former smokers, and 14.9{\%} were diabetic). Despite the high prevalence of risk factors, only 24.1{\%} were on aspirin, 16.1{\%} were on a statin, and only 7.8{\%} were taking an aspirin and statin. Use of preventive medications was even less common in patients with premature events, including aspirin (15.2{\%} vs 30.2{\%}, P value <.001), statins (11.1{\%} vs 19.5{\%}, P value <.001), and the combination (5.6{\%} vs 9.4{\%}, P value <.001). Conclusions: Approximately 70{\%} of a contemporary STEMI population did not have known CHD before their event, and > 40{\%} of those events would be considered premature. Despite the significant burden of cardiovascular risk factors, use of preventive therapy was alarmingly low in patients presenting with STEMI.",
author = "Miedema, {Michael D.} and Cohn, {Jay N} and Garberich, {Ross F.} and Thomas Knickelbine and Graham, {Kevin J.} and Henry, {Timothy D}",
year = "2012",
month = "8",
day = "1",
doi = "10.1016/j.ahj.2012.05.008",
language = "English (US)",
volume = "164",
pages = "259--267",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction

AU - Miedema, Michael D.

AU - Cohn, Jay N

AU - Garberich, Ross F.

AU - Knickelbine, Thomas

AU - Graham, Kevin J.

AU - Henry, Timothy D

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Background: Multiple medications have proven efficacy for the primary prevention of coronary heart disease (CHD), but the appropriate patient population remains controversial. Even in the presence of multiple cardiovascular risk factors, many patients are not considered high risk and are not offered preventive medications despite proven efficacy. Methods: We analyzed a prospective cohort of 1,710 consecutive ST-elevation myocardial infarction (STEMI) patients treated in a regional STEMI system from May 2007 to July 2010 and enrolled in a comprehensive database that includes preadmission medications. Results: Of the 1,707 patients analyzed, 1,180 (69.1%) did not have known CHD before their event; and 482 (41.7%) of those patients had premature events (men < 55 years old, women < 65 years old). In patients without known CHD, cardiovascular risk factors were abundant (52.1% had hypertension, 43.6% had dyslipidemia, 41.4% had a family history of CHD, 58.5% were current or former smokers, and 14.9% were diabetic). Despite the high prevalence of risk factors, only 24.1% were on aspirin, 16.1% were on a statin, and only 7.8% were taking an aspirin and statin. Use of preventive medications was even less common in patients with premature events, including aspirin (15.2% vs 30.2%, P value <.001), statins (11.1% vs 19.5%, P value <.001), and the combination (5.6% vs 9.4%, P value <.001). Conclusions: Approximately 70% of a contemporary STEMI population did not have known CHD before their event, and > 40% of those events would be considered premature. Despite the significant burden of cardiovascular risk factors, use of preventive therapy was alarmingly low in patients presenting with STEMI.

AB - Background: Multiple medications have proven efficacy for the primary prevention of coronary heart disease (CHD), but the appropriate patient population remains controversial. Even in the presence of multiple cardiovascular risk factors, many patients are not considered high risk and are not offered preventive medications despite proven efficacy. Methods: We analyzed a prospective cohort of 1,710 consecutive ST-elevation myocardial infarction (STEMI) patients treated in a regional STEMI system from May 2007 to July 2010 and enrolled in a comprehensive database that includes preadmission medications. Results: Of the 1,707 patients analyzed, 1,180 (69.1%) did not have known CHD before their event; and 482 (41.7%) of those patients had premature events (men < 55 years old, women < 65 years old). In patients without known CHD, cardiovascular risk factors were abundant (52.1% had hypertension, 43.6% had dyslipidemia, 41.4% had a family history of CHD, 58.5% were current or former smokers, and 14.9% were diabetic). Despite the high prevalence of risk factors, only 24.1% were on aspirin, 16.1% were on a statin, and only 7.8% were taking an aspirin and statin. Use of preventive medications was even less common in patients with premature events, including aspirin (15.2% vs 30.2%, P value <.001), statins (11.1% vs 19.5%, P value <.001), and the combination (5.6% vs 9.4%, P value <.001). Conclusions: Approximately 70% of a contemporary STEMI population did not have known CHD before their event, and > 40% of those events would be considered premature. Despite the significant burden of cardiovascular risk factors, use of preventive therapy was alarmingly low in patients presenting with STEMI.

UR - http://www.scopus.com/inward/record.url?scp=84864691358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864691358&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2012.05.008

DO - 10.1016/j.ahj.2012.05.008

M3 - Article

VL - 164

SP - 259

EP - 267

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 2

ER -